Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pelcitoclax (APG-1252) is a potent inhibitor of Bcl-2 and Bcl-xl proteins, demonstrating substantial antineoplastic and pro-apoptotic activities[1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $2,389 | 8-10 weeks | |
10 mg | $3,819 | 8-10 weeks | |
25 mg | $5,728 | 8-10 weeks | |
50 mg | $7,458 | 8-10 weeks |
Description | Pelcitoclax (APG-1252) is a potent inhibitor of Bcl-2 and Bcl-xl proteins, demonstrating substantial antineoplastic and pro-apoptotic activities[1]. |
In vitro | APG-1252 undergoes metabolic transformation into its reactive form, APG-1252-M1, which exhibits significant antitumor activity in (acute myeloid leukemia)[1]. |
In vivo | Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once daily for 10 days) treatment shows significantly greater inhibition of xenograft tumor growth compared to other groups[1]. |
Molecular Weight | 1281.84 |
Formula | C57H66ClF4N6O11PS4 |
Cas No. | 1619923-36-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.